Skip to content
The Nexus
DossierENTITY

VESPER program

Coverage of VESPER program in the Nexus archive.

Earliest in view: Jun 22 · 16:00 UTCMost recent: Jun 22 · 16:00 UTC
Co-mentioned in this coverage
berobenatidetopic1American Diabetes Associationorganization1GLP-1 agonisttopic1weight losstopic1
Recent coverage
  • HEALTHJun 22 · 16:00 UTCMEDPAGE TODAY
    Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?

    Updated phase II data from the VESPER program showed that patients achieved weight loss with weekly doses of the investigational GLP-1 agonist berobenatide. The study, presented at the American Diabetes Association annual meeting, is exploring whether monthly dosing can maintain these results.

VESPER program · Dossier · The Nexus